Amgen Inc.
AMGNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Amgen Inc. focuses on Drug Manufacturers - General services and products. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. With a market capitalization of $212.56B, it sits in mega-cap territory. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEP.
Market Cap
$212.56B
Beta
0.43
P/E (TTM)
24.44
P/E (Fwd)
16.11
EPS (TTM)
$16.09
EPS (Fwd)
$24.41
ROE
91.5%
ROA
8.7%
Cash
$13.99B
Total Debt
$57.30B
Free CF
$8.65B
52W Change
57.0%
Annual Financials
Cash vs Debt
Where AMGN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, AMGN finished 21.23% above its 150-day moving average ($361.39) and 24.28% above its 200-day moving average ($352.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMGN overbought or oversold?
At the September 2, 2026 close, AMGN's RSI(14) was 66.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Amgen Inc. carries $57.30B in total debt against $13.99B in cash reserves — debt is roughly 4.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $8.65B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 91.5% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $26.32B (2022) to $36.75B (2025), reflecting a 40% increase over the period.
AMGN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing AMGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.